DxS Ltd.
DxS is a personalized medicine company focused on providing genetic analysis services and technologies to enable the delivery of safe and effective medicines. The services provide support for drug development, diagnostic product development and pharmacodiagnostics. There is an increasing demand from the pharmaceutical industry for genetic analysis of clinical trial populations to help to understand individual variation in drug pharmacokinetics and pharmacodynamics. Since these studies are part of a clinical trial it is essential that they are performed in a high quality environment that meets relevant regulatory standards. DxS operates a genotyping service operation that fulfils all of these requirements. One of the expectations deriving from the growing use of pharmacogenetics during clinical development is that some of the genetic markers will be required as diagnostics to allow the identification of suitable patients for a therapy. This combination of a drug and a diagnostic is called personalized medicine. DxS have established a global network of alliance laboratories to allow the rapid translation of tests from clinical development into clinical diagnostics.